| Health board / Trust name |
Sitename |
Number of patients with Crohn's disease entered at your site |
Patients with Crohn's disease given 160/80 mg of ADA at induction |
Response to treatment |
Remission achieved |
Patients with at least one adverse event |
Patients with Crohn's disease on concomittant therapy, 5-ASA at induction |
Patients with Crohn's disease, treatment effective and discontinued at follow-up |
| Name of Health Board / Trust |
Name of site |
No of Crohn's disease patients entered |
No of Crohn's disease patients given 160/80 mg of ADA at induction |
Percentage (%) of Crohn's disease patients with a HBI drop of >3 at any follow up between 10 and 14 weeks |
Percentage (%) of Crohn's disease patients with a HBI score of <4 at any follow up between 10 and 14 weeks |
Percentage of patients who experienced at least one adverse event |
Percentage of all patients with Crohn's disease on 5-ASA as a concomittant therapy at initial treatment |
Percentage of patients with Crohn's disease who had their treatment effective and discontinued at follow-up |
| text |
text |
integer |
integer (Percentage) |
integer (Percentage) |
integer (Percentage) |
integer (Percentage) |
integer (Percentage) |
integer (Percentage) |
| text |
text |
integer |
0/0 (0%) |
0/0 (0%) |
0/0 (0%) |
0/0 (0%) |
0/0 (0%) |
0/0 (0%) |
